Abilify
Product Images NDC 43353-848

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 43353-848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10mg (43353 848)

Label for Aripiprazole (Abilify) 10 mg tablets, containing 15 tablets. The label includes dosage strength, quantity, storage instructions (store between 20-25°C), and repackaging information by Aphena Pharma Solutions - Tennessee, LLC. Manufacturer is Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. The label also notes prescription-only status.*

FDA Label Image

Bottle Label 20mg (43353 849)

Packaging label for Aripiprazole (Abilify) 20mg tablets. The label states the package contains 45 tablets and includes storage instructions between 20-25 degrees Celsius. It is manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also indicates this is an Rx only product and shows the NDC number 43353-0849-45.*

FDA Label Image

Bottle Label 30mg (43353 850)

Label for Aripiprazole (Abilify) 30mg tablets showing a quantity of 600 tablets. The label indicates the medication is repackaged by Aphena Pharma Solutions - Tennessee, LLC and originally manufactured by Otsuka Pharmaceutical Co., Ltd. in Tokyo, Japan. Storage instructions and dispensing requirements are included.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Aripiprazole Chemical Structure (Abilify 01)

Chemical structure of the active ingredient in ABILIFY, showing a complex molecule with two chlorine atoms, a piperazine ring, and a substituted quinolinone moiety linked by an ether chain.*

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Proportion Of Relapses To Any Mood Event For Abilify And Placebo Groups (Abilify 02)

A Kaplan-Meier time-to-event curve graph displaying the proportion of patients with relapse versus time in days from randomization. Two groups are compared: aripiprazole (solid blue line) and placebo (dotted red line), showing the cumulative relapse proportion over approximately 364 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.